RETATRUTIDE

RETATRUTIDE INFORMATION (GLP-1 + GIP + GLUCAGON)

BENEFITS

• Decreased appetite and cravings
• Weight loss
  Clinical trials demonstrated up to 24% weight loss, depending on the dose.
• Triple-action innovation: Combines GLP-1, GIP, and glucagon receptor activity for enhanced results.
• Compounded formulas include medications to minimize side effects like nausea.
• Convenient dosing: Weekly subcutaneous injections.
• Flexible treatment: Programs can be repeated as needed for sustained results.

COMMON SIDE EFFECTS

• Nausea
• Vomiting
• Diarrhea
• Constipation

RISK OF THYROID C-CELL TUMORS

Individuals with a personal or family history of Multiple Endocrine Neoplasia Syndrome Type 2 or medullary thyroid cancer should avoid using Retatrutide.

INFORMATION

Retatrutide is a next-generation medication that uniquely combines GLP-1, GIP, and glucagon receptor agonist mechanisms. It works by targeting multiple pathways in the brain to regulate appetite and energy expenditure. Clinical trials have shown weight loss of up to 24% compared to placebo, making it a promising option for those seeking effective weight management and metabolic health improvements.